Non-Hodgkin Lymphoma | Specialty

Sequencing Therapies for Follicular Lymphoma

January 13th 2017

Follicular Lymphoma: Consolidation and Maintenance

January 13th 2017

Follicular Lymphoma; Triggers to Initiate Therapy

January 13th 2017

Expert Highlights Efficacy of KTE-C19 CAR T-Cell Therapy in Non-Hodgkin Lymphoma

January 6th 2017

KTE-C19, an investigational CAR T-cell therapy, recently demonstrated positive results for patients with chemorefractory aggressive non-Hodgkin lymphoma.

R-CHOP Remains Frontline Standard in DLBCL, Says Expert

January 5th 2017

The regimen of rituximab plus CHOP chemotherapy has been the standard of care for patients with previously untreated diffuse large B-cell lymphoma for several years, and it appears it will remain that way for now, despite recent research to find novel alternatives.

Expert Explains WHO Classification Refinements in Hematologic Malignancies

December 30th 2016

Changes are underway in the field of hematologic malignancies, as the World Health Organization is publishing a revised classification of tumors of hematopoietic and lymphoid tissues—slated to be released in early 2017.

Dr. Neelapu on Interim Results of the Phase II ZUMA-1 Study in DLBCL

December 29th 2016

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses interim results of the phase II ZUMA-1 study in patients with diffuse large B-cell lymphoma.

FDA Grants JCAR017 Breakthrough Designation for Non-Hodgkin Lymphoma

December 21st 2016

JCAR017 has received an FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory, aggressive large B-cell non-Hodgkin lymphoma.

KTE-C19 Leads to High Response Rates in Refractory NHL

December 7th 2016

Almost 80% of patients with treatment-refractory non-Hodgkin lymphoma had objective responses following treatment with KTE-C19, a chimeric antigen receptor T-cell therapy targeting CD19.

Acalabrutinib Safe, Effective in Ibrutinib-Intolerant CLL/SLL

December 6th 2016

The investigational Bruton tyrosine kinase inhibitor acalabrutinib was shown to be well-tolerated in patients with chronic lymphocytic leukemia and small lymphocytic leukemia who display intolerance to ibrutinib (Imbruvica).

Frontline Obinutuzumab Significantly Improves PFS in Follicular Lymphoma

December 5th 2016

Combining obinutuzumab with chemotherapy in the first-line setting reduced the risk of disease progression or death by 34% versus rituximab plus chemotherapy in patients with follicular lymphoma, according to findings from the phase III GALLIUM study.

Acalabrutinib Monotherapy Effective for Richter Transformation

December 4th 2016

The next-generation BTK inhibitor acalabrutinib produced an objective response rate of 38.1% as a monotherapy for patents with Richter transformation.

Expert Emphasizes Need to Enhance Treatment Strategies for Indolent Lymphomas

November 22nd 2016

Investigators are exploring therapy options for patients with indolent lymphomas—including follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma—as rituximab regimens are proving to not be a long-term option for many patients.

RT Plus Chemo Significantly Improves PFS in Follicular Lymphoma

September 28th 2016

Chemoradiation for early-stage, low-grade follicular lymphoma led to significant improvement in progression-free survival compared with involved-field radiotherapy alone.

KTE-C19 Induces Complete Remissions in Phase II Lymphoma Study

September 27th 2016

Treatment with KTE-C19 demonstrated an objective response rate of 79% and a complete remission rate of 52% for patients with aggressive, chemorefractory non-Hodgkin's lymphoma.

FDA Approval Sought for Ibrutinib in Marginal Zone Lymphoma

September 27th 2016

A supplemental new drug application has been submitted to the FDA for the use of ibrutinib as a treatment for patients with marginal zone lymphoma.

Individualizing Therapy for Patients With Waldenstrom's Macroglobulinemia

September 16th 2016

Improved understanding of Waldenström's macroglobulinemia and expanded treatment options have made individualized treatment based on clinical indications a feasible strategy

CAR T-Cell Therapy Continues to Show Promise in Non-Hodgkin Lymphoma

September 13th 2016

Chimeric antigen receptor T-cells offer highly effective therapy for patients with minimal residual disease or bulky disease in both aggressive and indolent B-cell non-Hodgkin lymphomas.

The Future of Myeloma Research

July 27th 2016

Relapse Type and Monoclonal Antibody Choice in Multiple Myeloma

July 27th 2016